A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer - Concepedia

Concepedia

Publication | Closed Access

A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer

62

Citations

21

References

2012

Year

Angeles Alvarez Secord, Deanna Teoh, William T. Barry, Miao Yu, Gloria Broadwater, Laura J. Havrilesky, Paula S. Lee, Andrew Berchuck, Johnathan M. Lancaster, Robert M. Wenham

Clinical Cancer Research

Abstract

Due to the high incidence of myelosuppression with subsequent cycles, the recommended phase II dose of dasatinib is 150 mg daily in combination with paclitaxel and carboplatin. The combination was safe with evidence of clinical activity.

References

	Year	Citations

Page 1